跳到正文
原文
STAT 主站· Jason Mast·· 2026-10-21精选AI 评分73

Roivant:免疫调节药Lisraya在III期试验中治疗非感染性葡萄膜炎优于安慰剂

STAT+: Roivant says closely watched immune drug succeeded in new eye disease

AI 导读

Roivant与旗下公司Priovant表示,免疫调节片剂Lisraya在治疗非感染性葡萄膜炎的两项III期临床试验中优于安慰剂,共入组371例患者。该药已于8月获批用于罕见皮肤病皮肌炎,公司预计美国患者约7万至19万,其中超4万人已在使用Humira或类似疗法,拟于明年上半年申请批准以拓展适应症。

推荐理由

两项III期试验显示药物较安慰剂优,获批后将拓展至常见病市场。

正文 · 原文

Non-infectious uveitis was the next test for Lisraya pill

Roivant CEO Matt Gline at the STAT Summit last weekMaura Wayman for STAT

By Jason Mast

Oct. 21, 2026

General Assignment Reporter

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.

Roivant and its spinout Priovant said Wednesday that their immune-modifying pill Lisraya was more effective than placebo in treating the inflammatory eye disease non-infectious uveitis.

The results, from two Phase 3 trials spanning 371 patients, could unlock a new blockbuster market for Roivant. The company estimates that there are between 70,000 to 190,000 patients with the condition in the U.S., with over 40,000 of them already receiving Humira or a similar therapy. 

Roivant plans to file for approval in the first half of next year. An approval would expand the drug’s use beyond the rare skin disease dermatomyositis, which it was OK’d for in August.  

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

  1. General Assignment Reporter

    Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.

来源:STAT 主站 · statnews.com